Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.53 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575259 | 1.00 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL28072090 | 0.98 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL7705783 | 0.86 | ALDH1A1 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL243734 | 0.86 | ALDH1A1 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL243733 | 0.86 | ALDH1A1 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL7062539 | 0.86 | ALDH1A1 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL4421926 | 0.84 | MAPT (0.75) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL184544 | 0.84 | MAPT (0.75) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL168964 | 0.83 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL27985873 | 0.83 | STAT3 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100143961-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143961-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7579372-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579372-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2008011074-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2003099272-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | HDAC3 7/4885HDAC4 16/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.